OKYO vs. CYTH, DYAI, QNCX, SABS, ESLA, NKGN, SRZN, INKT, TARA, and AVRO
Should you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Cyclo Therapeutics (CYTH), Dyadic International (DYAI), Quince Therapeutics (QNCX), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), NKGen Biotech (NKGN), Surrozen (SRZN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), and AVROBIO (AVRO). These companies are all part of the "biological products, except diagnostic" industry.
Cyclo Therapeutics (NASDAQ:CYTH) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
OKYO Pharma has a net margin of 0.00% compared to OKYO Pharma's net margin of -1,864.03%. Cyclo Therapeutics' return on equity of 0.00% beat OKYO Pharma's return on equity.
OKYO Pharma has lower revenue, but higher earnings than Cyclo Therapeutics.
Cyclo Therapeutics received 3 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 77.78% of users gave Cyclo Therapeutics an outperform vote.
Cyclo Therapeutics presently has a consensus target price of $3.20, indicating a potential upside of 119.18%. OKYO Pharma has a consensus target price of $7.00, indicating a potential upside of 392.96%. Given Cyclo Therapeutics' higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Cyclo Therapeutics.
Cyclo Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.
In the previous week, Cyclo Therapeutics had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 5 mentions for Cyclo Therapeutics and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.41 beat Cyclo Therapeutics' score of -0.72 indicating that Cyclo Therapeutics is being referred to more favorably in the media.
Summary
OKYO Pharma beats Cyclo Therapeutics on 8 of the 14 factors compared between the two stocks.
Get OKYO Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OKYO Pharma Competitors List
Related Companies and Tools
